Menu

Press Releases

More than 100 Presentations at Leading Radiation Oncology Meeting Demonstrate High Value and Broad Utilization of Accuray’s Treatment Platforms

, , , ,

Data Supports Growing Use of CyberKnife® SBRT for Prostate Cancer SUNNYVALE, Calif., October 3, 2013 and ASTRO 2013 (Atlanta)– Accuray Incorporated (Nasdaq: ARAY) announced today that studies presented at the 55th Annual American Society for Radiation Oncology (ASTRO) Meeting in Atlanta, September 22 – 25, 2013 continue to reinforce evidence of clinical and quality of life benefits for […]

Secukinumab (AIN457) showed superiority over Enbrel® in clearing skin, according to pivotal Novartis Phase III psoriasis results at EADV

, ,

Secukinumab (AIN457) patients’ skin cleared faster and for longer than Enbrel® (etanercept) patients, beginning as early as Week 2[1] Study also showed twice as many secukinumab patients experienced clear or almost clear skin by Week 12 versus Enbrel[1] Head-to-head study of secukinumab and Enbrel part of largest clinical program completed in moderate-to-severe plaque psoriasis with […]

Real-world evidence showed superiority of Novartis’ Gilenya® to reduce MS relapse rates compared to interferons or glatiramer acetate

, ,

Real-world data showed Gilenya reduced the annualized relapse rate and risk of relapse by around 50% versus interferons or glatiramer acetate Reducing the frequency and probability of future relapses in patients with MS is a key treatment goal, as relapses can significantly advance an individual’s level of disability Recovering from a relapse can take weeks […]

Valeant Pharmaceuticals’ Bausch + Lomb Receives U.S. FDA Clearance For Novel Monthly Disposable Contact Lens

, , ,

LAVAL, Quebec, Oct. 3, 2013 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) and Bausch + Lomb announced today that the U.S. Food and Drug Administration (FDA) has issued marketing clearance for Bausch + Lomb’s newest frequent replacement silicone hydrogel contact lenses made with MoistureSeal™ Technology. Representing the category’s first new innovation […]

Valeant Pharmaceuticals Announces Approval Of Jublia® For The Treatment Of Onychomycosis In Canada

, , ,

LAVAL, Quebec, Oct. 3, 2013 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that its wholly owned subsidiary, Valeant Canada LP, has received notice that the New Drug Submission for Jublia® has been approved from the Canadian regulatory authority, Health Canada. Jublia® (efinaconazole 10% topical solution) is indicated for the […]

Nucletron, an Elekta Company, Receives US FDA 510(k) Clearance for Esteya Electronic Brachytherapy System for Treating Skin Cancer

, , , ,

Stockholm, October 2 – Esteya®, an electronic brachytherapy system, has received 510(k) clearance from the US Food and Drug Administration (FDA), enabling medical centers in the United States to offer their patients with skin cancer a new treatment option. Esteya is a new approach for high precision skin cancer treatment. The system relies on a small […]

Sandoz’s Nick Haggar named new EGA president

, ,

Holzkirchen, Germany, October 02, 2013 – The European Generic medicines Association (EGA) has named Sandoz’s Nick Haggar as the new incoming president of the European generic medicines industry body. Nick will take over the role on October 8, 2013 alongside his responsibilities at Sandoz as Head of Western Europe, Middle East and Africa. “I am delighted […]

Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence

, , ,

LAVAL, Quebec, Oct. 2, 2013 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced a partnership with the National Coalition Against Domestic Violence (NCADV) to help raise awareness of domestic violence. As part of the new domestic violence initiative, Valeant has pledged to donate a portion of sales from all Medicis and […]

Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis to be Presented at AASLD Annual Meeting

, , ,

Data Support Strong Statistical Association of PBC Biochemical Endpoint with Clinical Outcomes NEW YORK, Oct. 1, 2013 /PRNewswire/ — Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)(Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases such as primary biliary cirrhosis, today announced that two analyses by the Global Primary Biliary Cirrhosis (PBC) […]

AHIP Medicaid Summit 2013: Cardinal Health Specialty Solutions Chief Medical Officer Says Collaboration, New Delivery Models, Are Key to Bending the Cost Curve in Cancer Care

, ,

WASHINGTON, Sept. 24, 2013 /PRNewswire/ — As Medicare and Medicaid brace for a continued influx of beneficiaries – many of whom are older and more likely to have chronic conditions including cancer – all players across the continuum of care need to work together, now, to implement innovative new care delivery models that can improve […]

«‹ 40 41 42 43›»